Rivastigmine for cognitive impairment after spontaneous subarachnoid haemorrhage: a pilot study.

@article{Wong2009RivastigmineFC,
  title={Rivastigmine for cognitive impairment after spontaneous subarachnoid haemorrhage: a pilot study.},
  author={Gane K-S Wong and Rosanna Kit Man Wong and Vincent Chung Tony Mok and Alain Kai-Sing Wong and Dong-Sheng Fan and General Leung and Alexandre Chan and Wai Sang Poon},
  journal={Journal of clinical pharmacy and therapeutics},
  year={2009},
  volume={34 6},
  pages={
          657-63
        }
}
BACKGROUND AND OBJECTIVE Rivastigmine has been shown to be effective for patients with mild-to-moderate Alzheimer's disease. Its effect on cognitive impairment after aneurysmal subarachnoid haemorrhage has not been previously studied. The aim of the study is to evaluate the efficacy and safety of rivastigmine 3 mg/day over 12 weeks in patients with aneurysmal subarachnoid haemorrhage and persistent cognitive impairment. METHODS Twenty Chinese patients with spontaneous subarachnoid haemorrhage… CONTINUE READING
BETA